Table 4.
Annual incidence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and atomoxetine) by age category and gender
| Age Category | Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 |
|---|---|---|---|---|---|---|---|
|
6-12 years | |||||||
|
Female Incidence*1000 |
0.272 |
0.388 |
0.358 |
0.425 |
0.433 |
0.424 |
|
| 95% Cl (lb)*1000 |
0.181 |
0.277 |
0.252 |
0.309 |
0.314 |
0.307 |
|
| 95% Cl (ub)*1000 |
0.393 |
0.528 |
0.494 |
0.571 |
0.581 |
0.571 |
|
|
Male Incidence*1000 |
1.982 |
2.036 |
2.013 |
2.476 |
2.331 |
2.101 |
|
| 95% Cl (lb)*1000 |
1.725 |
1.776 |
1.753 |
3.188 |
2.049 |
1.833 |
|
| 95% Cl (ub)*1000 |
2.267 |
2.325 |
2.300 |
2.793 |
2.642 |
2.397 |
|
|
Total Incidence*1000 |
1.145 |
1.229 |
1.201 |
1.470 |
1.400 |
1.278 |
|
| 95% Cl (lb)*1000 |
1.005 |
1.084 |
1.058 |
1.311 |
1.243 |
1.128 |
|
| 95% Cl (ub)*1000 |
1.300 |
1.388 |
1.359 |
1.643 |
1.570 |
1.441 |
|
|
13-17 years | |||||||
|
Female Incidence*1000 |
0.102 |
0.178 |
0.168 |
0.224 |
0.318 |
0.270 |
|
| 95% Cl (lb)*1000 |
0.0471 |
0.095 |
0.090 |
0.133 |
0.208 |
0.169 |
|
| 95% Cl (ub)*1000 |
0.210 |
0.304 |
0.288 |
0.354 |
0.465 |
0.409 |
|
|
Male Incidence*1000 |
0.666 |
1.160 |
1.063 |
1.174 |
1.052 |
0.977 |
|
| 95% Cl (lb)*1000 |
0.496 |
0.937 |
0.852 |
0.954 |
0.845 |
0.777 |
|
| 95% Cl (ub)*1000 |
0.876 |
1.422 |
1.309 |
1.429 |
1.295 |
1.212 |
|
|
Total Incidence*1000 |
0.400 |
0.691 |
0.631 |
0.710 |
0.691 |
0.629 |
|
| 95% Cl (lb)*1000 |
0.303 |
0.566 |
0.514 |
0.587 |
0.571 |
0.514 |
|
| 95% Cl (ub)*1000 |
0.516 |
0.836 |
0.767 |
0.851 |
0.829 |
0.762 |
|
|
18-24 years | |||||||
|
Female Incidence*1000 |
0.013 |
0.037 |
0.000 |
0.023 |
0.022 |
0.021 |
|
| 95% Cl (lb)*1000 |
0.000 |
0.008 |
0.000 |
0.003 |
0.003 |
0.002 |
|
| 95% Cl (ub)*1000 |
0.071 |
0.108 |
0.044 |
0.082 |
0.079 |
0.074 |
|
|
Male Incidence*1000 |
0.022 |
0.096 |
0.041 |
0.070 |
0.087 |
0.159 |
|
| 95% Cl (lb)*1000 |
0.003 |
0.044 |
0.011 |
0.028 |
0.040 |
0.092 |
|
| 95% Cl (ub)*1000 |
0.080 |
0.182 |
0.106 |
0.144 |
0.165 |
0.254 |
|
|
Total Incidence*1000 |
0.018 |
0.069 |
0.022 |
0.048 |
0.056 |
0.093 |
|
| 95% Cl (lb)*1000 |
0.004 |
0.036 |
0.006 |
0.022 |
0.028 |
0.056 |
|
| 95% Cl (ub)*1000 |
0.052 |
0.120 |
0.057 |
0.091 |
0.101 |
0.145 |
|
|
25-45 years | |||||||
|
Female Incidence*1000 |
0.000 |
0.009 |
0.006 |
0.011 |
0.003 |
0.016 |
|
| 95% Cl (lb)*1000 |
0.000 |
0.002 |
0.001 |
0.003 |
0.000 |
0.006 |
|
| 95% Cl (ub)*1000 |
0.011 |
0.025 |
0.020 |
0.028 |
0.015 |
0.036 |
|
|
Male Incidence*1000 |
0.008 |
0.011 |
0.022 |
0.013 |
0.019 |
0.027 |
|
| 95% Cl (lb)*1000 |
0.002 |
0.003 |
0.009 |
0.004 |
0.008 |
0.013 |
|
| 95% Cl (ub)*1000 |
0.024 |
0.028 |
0.043 |
0.031 |
0.039 |
0.049 |
|
|
Total Incidence*1000 |
0.004 |
0.010 |
0.014 |
0.013 |
0.011 |
0.022 |
|
| 95% Cl (lb)*1000 |
0.001 |
0.004 |
0.007 |
0.006 |
0.005 |
0.012 |
|
| 95% Cl (ub)*1000 |
0.012 |
0.020 |
0.025 |
0.023 |
0.021 |
0.035 |
|
|
>45 years | |||||||
|
Female Incidence*1000 |
0.004 |
0.000 |
0.000 |
0.002 |
0.002 |
0.000 |
|
| 95% Cl (lb)*1000 |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
| 95% Cl (ub)*1000 |
0.013 |
0.007 |
0.007 |
0.10 |
0.010 |
0.006 |
|
|
Male Incidence*1000 |
0.000 |
0.000 |
0.004 |
0.002 |
0.004 |
0.009 |
|
| 95% Cl (lb)*1000 |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
0.003 |
|
| 95% Cl (ub)*1000 |
0.008 |
0.007 |
0.014 |
0.011 |
0.014 |
0.021 |
|
|
Total Incidence*1000 |
0.002 |
0.000 |
0.002 |
0.002 |
0.003 |
0.004 |
|
| 95% Cl (lb)*1000 |
0.000 |
0.000 |
0.000 |
0.000 |
0.001 |
0.001 |
|
| 95% Cl (ub)*1000 | 0.007 | 0.004 | 0.007 | 0.007 | 0.008 | 0.010 | |